A number of other equities research analysts have also recently commented on the company. Zacks Investment Research cut OncoSec Medical from a buy rating to a hold rating in a research note on Wednesday, July 24th. Maxim Group reissued a buy rating and issued a $10.00 price objective on shares of OncoSec Medical in a research note on Friday, June 28th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $19.75.
OncoSec Medical stock traded down $0.05 during mid-day trading on Thursday, reaching $2.06. The stock had a trading volume of 9,090 shares, compared to its average volume of 144,214. OncoSec Medical has a fifty-two week low of $2.02 and a fifty-two week high of $19.60. The company has a 50-day simple moving average of $2.44.
A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock worth $248,000 after acquiring an additional 163,405 shares during the period. Northern Trust Corp lifted its holdings in OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 28,914 shares during the period. Bank of New York Mellon Corp lifted its holdings in OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 83,150 shares during the period. Finally, BlackRock Inc. lifted its holdings in OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock worth $311,000 after acquiring an additional 240,843 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.